NCT04239859View on ClinicalTrials.gov

Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Plaque Psoriasis
Interventions
BIOLOGICAL

secukinumab

Secukinumab for 6 months, given at weeks 0, 1, 2, 3 and 4, then monthly till 6 months. 300mg per administration, subcutaneously.

DRUG

Methotrexate

Oral tablet up to 15mg per week

DRUG

Cyclosporin A

Oral capsule up to 200mg per day

DRUG

Acitretin

Oral capsule up to 25mg per day

Trial Locations (1)

169608

Singapore General Hospital, Outram Park

All Listed Sponsors
collaborator

Translational Immunology Institute

UNKNOWN

lead

Singapore General Hospital

OTHER